EN DE
Watch Journey Medical Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Journey Medical Corp (DERM) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Journey Medical Corp stock $3.89, price $4.42, that is 12.0% below the price, quality 37 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

JM Journey Medical Corp logo Thin data Nov 10, 2026

Journey Medical Corp

DERM · US
Expensive, weak quality

Our calculation puts a fair price 12% below what the stock costs today.

Revenue last quarter +23% vs. a year ago.
Moderate debt
Fair value $3.89 · Overvalued
Quality 37/100
Weak Growth (revenue 3y −5.7 %/yr in USD)
Loss-making · -9.0% net margin (TTM)
Negative free cash flow
Trails peers (2/10)
Narrow moat 9/100 · thin data
Thin data
Estimate
Watch Journey Medical Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$9.90 $1.04 Fair Value $3.89 Nov 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $1.04 – $9.90 · fair‑value band $2.92 – $4.86 · the $4.42 price screens above the $3.89 fair value. As of Nov 10, 2026.

Follow Journey Medical in your weekly email

Every Wednesday you see whether Journey Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.

Show moreShow less

The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis.

The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Stock analysis

Journey Medical Corp (DERM) currently trades at $4.42, while our estimate is $3.89, 12% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $2.92 (bear) to $4.86 (bull), the price of $4.42 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Journey Medical Corp reported revenue of $61.9M in FY2025 versus $63.1M in FY2021, a compound −0.5%/yr. Reported net income was −$11.4M in FY2025.

Key figures

Market cap $146M Micro · P/S ratio 2.14 · EPS (TTM) $−0.2200 · Net margin −9.0% · Return on equity −23.8% · Return on assets (EBIT) −18.1% (5-year average) · Operating margin 2.5% · Revenue (TTM) $68.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (low confidence).

What moves the price

The share trades about 52% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −12%, DERM screens cheaper than that median.

Fair Value

Bear $2.92 Fair Value $3.89 Bull $4.86
Price $4.42 · Downside -12.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 23
How much profit the company makes from its sales and capital
Quality Growth 59
Are margins and returns getting better?
Cashflow 35
Do the profits arrive as real cash?
Financial strength 46
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 27
How calm the share price moves, does not count
Price momentum 13
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 8 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 19/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+10.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.8%
Start year 2020 (pandemic). Over 10 years: +23.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
17.6% (2020) → −13.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

DERM screens overvalued: fair value 12% below the price. Compare with Merck KGaA →

Compare Journey Medical Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −12.0% · Below median
Profitability
Return on assets −12.1% · Bottom 25%
Net margin (12 months) −9.0% · Bottom 25%
Operating margin (12 months) 2.5% · Below median
Growth and dividend
Revenue growth (quarter YoY) 23.3% · Top 25%
Balance sheet
Debt / equity 0.79× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 4.58× · Priciest 25%
P/S (12 months) 2.14× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)17 · sector 18
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)60 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs DERM
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs DERM
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs DERM
Haleon plc HLN $9.06 $8.62 −5% vs DERM
Merck KGaA MRK €149.35 €109.18 −27% vs DERM
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs DERM
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs DERM
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs DERM
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs DERM
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs DERM

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Journey Medical Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Journey Medical Corp Fair Value". https://www.fairvalue-calculator.com/stock/DERM

Frequently asked questions

Is Journey Medical Corp (DERM) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $3.89 versus a price of $4.42, about 12% lower (overvalued).
What is the fair value of DERM?
Our estimate for Journey Medical Corp is $3.89 (as of Nov 10, 2026), built from audited fundamentals. The current price: $4.42.
What is the quality score of DERM?
Journey Medical Corp has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Journey Medical Corp (DERM)?
Our calculated price target is the estimate of $3.89 (as of Nov 10, 2026). Cautious scenario $2.92, optimistic scenario $4.86. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Journey Medical Corp stock forecast for 2026?
Our estimate puts fair value at $3.89, about 12% lower versus a price of $4.42 (overvalued). Cautious scenario $2.92, optimistic scenario $4.86. The calculation is refreshed regularly with new filings.
What is the revenue of Journey Medical Corp (DERM)?
Journey Medical Corp reported trailing-twelve-month revenue of about $68.2M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Journey Medical Corp (DERM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Journey Medical Corp it is $3.89 per share (as of Nov 10, 2026), against a price of $4.42.
Is Journey Medical Corp stock overvalued or undervalued in 2026?
As of Nov 10, 2026, DERM trades above its calculated fair value: price $4.42, fair value $3.89, a gap of about −12% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DERM?
No. The price is what the market pays today ($4.42); the fair value is what the company's own numbers justify ($3.89). For Journey Medical Corp the two are $0.5300 per share apart. That gap is exactly why we show both numbers side by side.
How much is Journey Medical Corp worth?
The market values Journey Medical Corp at about $146M (market capitalisation, as of Nov 10, 2026). Per share that is $4.42; our models calculate a fair value of $3.89 per share.
What do the bullish and bearish scenarios say about DERM?
Our models span a range for Journey Medical Corp: cautious scenario $2.92, base $3.89, optimistic $4.86 per share (as of Nov 10, 2026, price $4.42). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Journey Medical Corp (DERM)?
Balance-sheet figures for Journey Medical Corp (as of Nov 10, 2026): return on equity −23.8%, debt of 0.79 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is DERM from its 52-week high?
Journey Medical Corp trades at $4.42, about 52% below its 52-week high of $9.26 and 3% above the low of $4.30 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $3.89 is for.
Which stocks are comparable to Journey Medical Corp?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Journey Medical Corp stock attractive at the current price?
The data as of Nov 10, 2026: price $4.42, calculated fair value $3.89 (−12%), Quality Score 37/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Journey Medical Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Journey Medical Corp (DERM)?
The closing price on Nov 10, 2026 was $4.42. Our estimate is $3.89, about 12% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Journey Medical Corp right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Journey Medical Corp

How large is the market capitalisation of Journey Medical Corp (DERM)?
The market capitalisation of Journey Medical Corp is $146M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Journey Medical Corp (DERM)?
The price-to-sales ratio of Journey Medical Corp is 2.14 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Journey Medical Corp (DERM)?
Earnings per share at Journey Medical Corp are $−0.2200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Journey Medical Corp (DERM)?
The net margin of Journey Medical Corp is −9.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Journey Medical Corp (DERM)?
The return on equity (ROE) of Journey Medical Corp is −23.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Journey Medical Corp (DERM)?
On an EBIT basis the return on assets of Journey Medical Corp is −18.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Journey Medical Corp (DERM)?
The operating margin of Journey Medical Corp is 2.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Journey Medical Corp (DERM)?
Revenue at Journey Medical Corp is growing +23.3% versus a year earlier (3y avg −5.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Journey Medical Corp (DERM) generate?
The free cash flow of Journey Medical Corp is −$12.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Journey Medical Corp (DERM) carry?
The net debt of Journey Medical Corp is $1.3M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Journey Medical Corp in the live analysis

One click puts Journey Medical Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.